Adipotide (10mg)
Adipotide is a synthetic peptidomimetic that targets prohibitin in the blood vessels of white adipose tissue and delivers a pro-apoptotic sequence to destroy these vessels, causing targeted fat mass reduction. Clinical development was halted after a Phase 1 trial due to safety concerns. Once daily subcutaneous administration with careful titration.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
Adipotide is a peptidomimetic designed to selectively target blood vessels within white adipose tissue by binding to prohibitin-1 on the vascular endothelium. Upon binding, it delivers a pro-apoptotic sequence that triggers vessel destruction, cutting off the blood supply to adipocytes. Preclinical studies in obese rodents showed ~30% weight reduction, while obese primates experienced ~11% weight loss in 4 weeks.
Quick Start
- Reconstitution: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
- Starting Dose: 250 mcg daily; titrate up by 250 mcg every 2 weeks.
- Storage: Lyophilized: −20 °C; reconstituted: 2–8 °C; avoid freeze-thaw cycles.
Titration Schedule (3 mL = ~3.33 mg/mL)
Route: Subcutaneous | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 250 mcg | 7.5 Units (0.07 mL) |
| Weeks 3–4 | 500 mcg | 15 Units (0.15 mL) |
| Weeks 5–6 | 750 mcg | 22.5 Units (0.22 mL) |
| Weeks 7–8 | 1000 mcg (1.0 mg) | 30 Units (0.30 mL) |
Studies report administration once daily subcutaneously. This protocol uses the most practical dilution (3.0 mL) and starts at a conservative dose with gradual titration to mitigate potential renal side effects.
Related compounds
Reconstitution Steps
- Draw 3.0 mL of bacteriostatic water with a sterile syringe.
- Slowly inject it down the side of the vial; avoid foaming.
- Gently swirl until fully dissolved (do not shake).
- Date and refrigerate at 2–8 °C, away from light.
Protocol Overview
- Goal: Targeted fat mass reduction through vascular targeting in adipose tissue.
- Schedule: Daily subcutaneous injections for 4–8 weeks (cautious approach due to limited human data).
- Storage: Lyophilized frozen; reconstituted refrigerated.
Dosing Protocol
- Start: 250 mcg daily for Weeks 1–2; increase by 250 mcg every 2 weeks.
- Target: Up to 1000 mcg (1.0 mg) daily by Weeks 7–8 (if tolerated).
- Frequency: Once daily (subcutaneous).
- Cycle Duration: 4–8 weeks (extend with extreme caution).
- Break between cycles: 8-week pause before repeating due to safety concerns.
Washout & Cycle Restart
When can I restart?
8-week pause before repeating due to safety concerns.
Minimum wait period: 8 weeks
Storage Instructions
- Lyophilized: −20 °C in dry, dark conditions.
- Reconstituted: 2–8 °C; avoid freeze-thaw cycles.
- Allow vials to reach room temperature before opening.
Important Notes
- Important: Clinical development was halted due to safety concerns (reversible nephrotoxicity at high doses). For educational purposes only.
Potential Benefits & Side Effects
Potential Benefits:
- Targeted fat mass reduction (up to 30% in rodents, ~11% in primates)
- Mechanism specifically targets adipose tissue vasculature
- Data from preclinical studies only
Potential Side Effects:
- Clinical development was halted due to safety concerns
- Dose-dependent, reversible nephrotoxicity in preclinical studies
- Mild local injection site reactions (redness, swelling)
- Long-term human safety profile: unknown
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Adipocyte destruction — potential local risks
Adipotide (FTPP) targets adipose tissue vasculature, causing necrosis. In primates, reversible renal tubular damage was observed. Clinical development was discontinued.
📄 Sci Transl Med 2011Nephrotoxicity (animal models)
In rhesus monkeys, Adipotide caused dose-dependent kidney damage (elevated creatinine). Reversible after discontinuation, but serious concern.
📄 Sci Transl Med 2011References
- Science Translational Medicine — Peptidomimetic targeting of white fat causes weight loss in obese primates
View Source - MD Anderson Cancer Center — Obese monkeys lose weight on drug that attacks fat's blood supply
View Source - Arrowhead Pharmaceuticals — Adipotide Phase 1 trial – first patient dosed
View Source - ScienceDaily — Obese monkeys lose weight – targeting blood vessels of fat tissue
View Source
Recommended Supplements
Vitamin B12 (Methylcobalamin)
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Protein / Collagen
Fiber Supplement (Psyllium)
External Sources & Regulatory Status
Regulatory Approvals
Research-only — Adipotide (clinical development halted after Phase 1)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →